Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like pmcb hasn't "hired" anyone new. Helps to read the 10's so as not to misinform with ignorance.
"We have four full-time employees and five consultants who function as our Chief Scientific Officer, Director of Diabetes Program Development, Director of Cannabis Program Development, Chairman of the Advisory Board and Senior Strategic Advisor."
https://www.sec.gov/Archives/edgar/data/1157075/000168316817001881/pharmacyte_10k-043017.htm
Pmcb Fantastic close today -1.4%. Another Bloody Red Day!! what's that, 4 down days in a row? Can anyone make the bleeding stop?
Do you think if there was an nda signed pmcb would be at .06 and selling shares outside of the market for 1/2 of that?? I don't think so!
All comes down to commons. Some have them, some don't. Pmcb is counting on the latter.
Try talking to Peter Lebowitz he's the head in the Global therapeutic and oncology department. I believe him.
Nope. I emailed Janssen and they have never heard of Pharmacyte or cell in a box. Although they had heard of novacaps aka (ciab)but felt the technology had to many issues and not enough "potential".
Boy if I had a penny for every time I heard something like this in the last 3 years I'd have enough to buy up the float on apple. Pmcb is king of leading its investors on, delaying, reneging on statement, ect....
"Too many pieces
This is going to be an exciting month"
Hope everyone took advantage of my reference example on how accumulation really looks and PERFORMS compared to the dud pmcb.
Congrats! I bet it does feel good to be out of this pos. Very true about if there was even a partner lined up pmcb wouldn't be selling 100's of millions of shares would they especially at high discount to market $.
I've said in the past, all comes down to common sense! Welcome to the elite!
Quote:
"If there was a partnership like many have speculated then what is the need to sell so many shares. I took a quick 40% profit and got out and feel good about it after looking through that filing."
Great so if investors say CIAB is golden what's the point of FDA?
Eh who needs an immune system, minor details LOL. Let's overlook these facts and pretend pmcb CIAB is going to cure the world!!
Quote:
"Furthermore, when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal."
Your right 2 small trials nearly 20 years ago.
Dr. Manuel Hidalgo:
"the previous studies were small, and we need additional data.”
Pmcb:
Although the FDA may accept data from clinical trials conducted outside the U.S., acceptance of this data is subject to certain conditions imposed by the regulatory agencies outside of the U.S. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the population in the country in which the clinical trial is being conducted. The data must be applicable to the U.S. population and medical practice in the U.S. in ways that the FDA deems clinically meaningful. Generally, the patient population for any clinical trials conducted outside of the U.S. must be representative of the population for whom we intend to seek approval in the U.S.
In the bulls defense though pmcb and its buddy at SMMG love to twist words to confuse the hell out of its investors.
Quote:
Two previous clinical trials were carried out in Europe in 1998, 1999 and 2000"
PMCB = RED
QUOTE:
"Are we red or green on Monday?"
Yup that rules pmcb out since we all know CIAB is not a DRUG.
Great news for ViaCyte and those with T1 diabetes! Last paragraph direct jab at pmcb!
"Regardless, it's great news for anyone with the condition, especially considering so many stem cell therapies have turned into predatory and useless treatments."
Nice find of yet another BULLSHIT lie told by pmcb.
SILVER SPRING, MD–(Marketwired – Nov 4, 2013) – PharmaCyte Biotech, Inc. (OTCQB: NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that cloning of the cancer-drug-activating cells required for PharmaCyte Biotech’s future Phase 3 clinical trials has begun at Inno Biologics in its cGMP-compliant facilities.
Following receipt by Inno Biologics of four vials of frozen cells capable of converting the well-known anticancer prodrug ifosfamide into its active cancer-killing form, one of the vials was thawed and the cells grown in culture. The cells, which were previously grown by ViruSure in Vienna, were successfully thawed, and approximately 97% of the cells were found to be viable. The contents of the vial were tested and found to be free of the “adventitious agents” bacteria, fungi, and mycoplasma.
Great wouldn't happen to have that crl would you?
Quote:
"Fda saw the pmcb previous clinical trials... saw that they have attracted the best of the best for pancreatic cancer...von hoff probably put in a good word as he worked with cell in box on ascites...fda said you know what...provide us with some additional data (currently being worked on)...and we will let you perform a pivotal clinical trial..."
No FDA data to back any of these claims up. All wishful thinking.
Well it's been 20 years so what do we call that?
"It takes an average of 12 years to get a new drug to market. This is a marathon, not a sprint."
Do we see the differences here? IFM Therapeutics (private company) developed their treatment aka as a (new therapy) while pmcb took an 20 year outdated unwanted treatment and is trying to pass it off as new.
Not only that but IFM was financially backed by big pharma who obviously seen potential unlike pmcb.
"Cambridge Upstart IFM Therapeutics Banks $27 Million from Investors Like Novartis AG (NVS) and Atlas Venture"
http://www.biospace.com/News/cambridge-upstart-ifm-therapeutics-banks-27/424115
Will Ken Waggoner face the same charges and convictions as Martin Shkreli?
"Former drug company executive Martin Shkreli could spend years in prison for Friday's investor fraud conviction if the judge focuses on the intended impact of his crime and his "Pharma Bro" social media antics, according to legal experts."
Tic Toc
Now it takes time?? What happened:
If the FDA doesn't issue any comments or notes within the thirty days following the pre-IND meeting we could be looking at a clinical trial start date of Feb 17, 2017 - which puts the 6-month hard stop at approximately mid-August 2017!
Oh ya then why pmcb paying Td2? Shouldn't it be the other way around.
That would be like renting a car and the rental place paying you to rent it.
I'm not suggesting he a terrible Dr.
What im saying is some, ok a lot of the companies he's involved with suck. They fail regardless if he's on the board or not. Some of these failures are loaded with good doctors.
Guess what, Still FAIL!
So if anyone thinks pmcb can't fail because of Dr. DVH or whatever Dr. better rethink their theory.
It's just a matter of time before pmcb joins the failure list.
Hmm according to the link you gave it says the following (below) which we all know now is BULLSHIT!!
The Cell-in-a-Box® capsules are produced in a cGMP-compliant facility managed by Austrianova. PharmaCyte is preparing to conduct a phase 2b trial in patients with borderline operable or non-operable pancreatic cancer, expected to begin in the third quarter, that will compare its treatment head-to-head with gemcitabine combined.
PharmaCyte plans to conduct a separate trial, also beginning this quarter (3rd 2015) to investigate the role of Cellin-the-Box® in reducing pain associated with tumor growth.
Thanks for the links proving pmcb lies through their teeth!!
Btw where's the results from the mice?? Only been 2 years.....
"In July, the company initiated a second preclinical study in mice to assess the effectiveness of its pancreatic cancer treatment on the rate of accumulation of malignant ascites fluid in pancreatic cancer and other abdominal tumors, testing four separate doses of ifosfamide with the goal of setting parameters for the design of a phase 1. "
Hey look Dr D von hoff is on the board of yet another stinky pinky!
EAST SETAUKET, N.Y., Jan. 7, 2014 /PRNewswire/ -- John S. Kovach, M.D., President and CEO, Lixte Biotechnology Holdings, Inc. (LIXT.PK), announces the appointment of Daniel D. Von Hoff, MD, FACP, to the company's Scientific Advisory Board.
"We are extremely pleased that Dr. Von Hoff has joined the Lixte Scientific Advisory Board. Dr. Von Hoff is internationally recognized as a leader in the pre-clinical and clinical development of new anti-cancer drugs. He and his colleagues were instrumental in the advancement of many anti-cancer drugs now used routinely in cancer care. We very much look forward to Dr. Von Hoff's suggestions regarding the most efficient clinical development of our proprietary anti-cancer compounds," says Dr. Kovach.
And another failure... (Aptose) with none other Dr Von Hoff presiding.
Aptose Delays Lead Cancer Drug Development (APTO)
By Shobhit Seth | January 27, 2017 — 12:54 PM EST
http://www.investopedia.com/news/aptose-delays-lead-cancer-drug-development-apto/?lgl=rira-baseline-vertical
Aptose also appointed Daniel D. Von Hoff, M.D., to serve as a special advisor to fulfill the functions of the Company’s Senior Vice President of Medical Affairs. Dr. Von Hoff is an independent contractor and advisor but is not an employee of Aptose. The Board, after receiving the recommendation of a special committee composed of independent directors formed in September 2013 to review strategic alternatives available to the Company, designed to secure the long-term financial and operational sustainability of the Company with a view to enhance shareholder value, unanimously approved the appointments. In doing so, the Board determined that such appointments were in the best interest of Aptose, as they were considered to enhance the management team and advisory team with the addition of two seasoned and experienced biotechnology executives bringing extensive clinical development and capital raising experience and improving the awareness and presence of the Company in the United States.
https://www.sec.gov/Archives/edgar/data/882361/000117184317001838/f20f_032917.htm
Another company (Arqule) that failed trials with Dr Von Hoff at the helm along with a boatload of other doctors.
Daniel D. Von Hoff Appointed to Scientific Advisory Board
Daniel D. Von Hoff, M.D. joins Gerard I. Evan, Ph.D., Alfred L. Goldberg, Ph.D., William G. Kaelin, Jr., M.D., Arthur B. Pardee, Ph.D., John L. Ryan, M.D., Ph.D., Sam R. Saks, M.D., and Robert A. Weinberg, Ph.D. on the ArQule Scientific Advisory Board.
Daniel D. Von Hoff, M.D., is Professor of Medicine, Molecular and Cellular Biology and Pathology, and Director of the Arizona Health Sciences Center’s Cancer Therapeutics Program at The University of Arizona and Director of Translational Research at the Translational Research Institute (TGen). He is also Chief Scientific Officer for US Oncology Research. Dr. Von Hoff is developing molecularly targeted anticancer therapies, with particular concentration in the area of pancreatic cancer. He and his colleagues were involved in the development of mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine and CPT-11 and multiple other agents. His laboratory specializes in in-vitro drug sensitivity testing to individualize patient treatment, gene amplification and targeting telomere maintenance mechanisms. He is the author of over 503 papers, 126 book chapters and 843 abstracts. Dr. Von Hoff is past president of the American Association for Cancer Research, a fellow of the American College of Physicians and a member and past board member of the American Society of Clinical Oncology. He is associated in various capacities with many prominent publications, as founder, editor or co-editor, including “Investigational New Drugs — The Journal of New Anti-Cancer Agents,” “Clinical Cancer Research,” and “Molecular Cancer Therapeutics.”
https://www.sec.gov/Archives/edgar/data/1019695/000095013504003620/b513058kexv99w1.htm
Here is from their (Genta) last 10k in 2012 right before failure and ch 7 bankruptcy. Wow who would have thought Dr von hoff would be a part of such a scam??
Daniel D. Von Hoff, M.D., F.A.C.P., 64, has been a member of our Board since January 2000. Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents now used routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, CPT-11, and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies. He and his laboratory are especially focusing on discovery and development of new target agents for the treatment of pancreatic cancer. Dr. Von Hoff has published more than 530 papers, 129 book chapters, and more than 900 abstracts. Dr. Von Hoff served on the President’s National Cancer Advisory Board from 2004 to 2010. Dr. Von Hoff is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He was a founder of ILEX Oncology, Inc. (acquired by Genzyme-Sanofi Aventis). He was also founder and Editor Emeritus of Investigational New Drugs - The Journal of New Anticancer Agents, and Editor-in-Chief of Molecular Cancer Therapeutics. Among other appointments, Dr. Von Hoff is: Professor of Medicine at the University of Arizona College of Medicine; Clinical Professor of Medicine at the Mayo Clinic; Founder Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, AZ; and Chief Scientific Officer at Scottsdale Healthcare, Inc. and U.S. Oncology, Inc.
The Board believes that Dr. Von Hoff’s background in the development of anti-cancer compounds, along with his extensive medical background, position him to make valuable contributions to Genta as a member of its Board.
It can't happen to pmcb can it?? Here's a biotech that failed miserably while robbing millions from its investors.
(Genta Incorporated)
Here's the kicker
Dr Daniel Von Hoff was a board director.
Unlike pmcb Dr Daniel Von Hoff was a share holder of Genta!
Genta failed multiple trials with many Dr's at the helm!
The Street:
Genta ( GNTAQ) filed for Chapter 7 bankruptcy liquidation, thereby ending 24 years of repeated clinical failures, multiple FDA rejections, countless toxic financings and epically piggish executive behavior.
Before the Genta corpse rots into distant memory, I thought it might be helpful to document the company's colorful and painful history. The Genta story is a warning to biotech investors showing how chronic clinical failure can lead to soul-crushing shareholder dilution.
https://www.google.com/amp/s/www.thestreet.com/amp/story/11747573/1/genta-1998-2012.html
Old 10k showing Dr Von Hoff
https://www.sec.gov/Archives/edgar/data/880643/000095013502002282/b42233a2e10-ka.txt
If so then why are the only ones who believe this are investors and pmcb?
Why are clinical trials even needed if CIAB is already "superior" as stated here??
Why hasn't any other bio scooped this up in the last 20 years for measly $2 million???
Why only a penny stock attorney with NO biotechnology experience (Ken Waggoner) picked up CIAB when again no other Bio was interested?
Why did Ken W fail to mention his role at China-Tel when he came to pmcb?
Why is nobody interested in backing (financially) pmcb not even JDRF??
Why are no insiders buying if pmcb has potential??
Why is pmcb no longer using Austrianova for their cell manufacture?
Why is pmcb selling shares a 1/2 the market value if they think CIAB is golden??
Why why why??
Quote:
"No need to challenge the technology...it's...the...best. "
;) Interesting isn't it. Unfortunately for pmcb, investors are not falling for the pump pieces as in the past. Time has come for Pmcb to put up or shut up.
I'm interested in how pmcb going to fund any trials with $3.4m. Pmcb has a cash burn rate of $4.4m. Salaries alone $700k.
ViaCyte has required over $50m with the help of financing partners:
JDRF
Gore
CIRM
Janssen
1 Unknown
IND Application alone cost $550,000 in 2015. https://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm093484.htm
Quote:
Was the Canadian hint to lift us to 75m?
So shares could continue being sold and revenue raised?
It did happen a short time before end of quarter and the company was drifting below 75m at that time?
Interesting that watcher1 alerted us to the Facebook hint, encouraged us to join the dots and buy shares and then watcher1 and kws post disappeared."
Yes pmcb's financing is gone unless they can reach the 75m market cap again.
10k
To be eligible to use Form S-3 for a registered offering of our securities to investors, either: (i) the aggregate market value of our common stock held by non-affiliates would have to exceed $75 million; or (ii) our common stock would have to be listed and registered on a national securities exchange. If we do not meet either of those eligibility requirements, we would be precluded from conducting a registered offering of our securities to investors by means of filing a Form S-3 or effecting a “shelf” offering until we meet one of these requirements.
https://www.sec.gov/Archives/edgar/data/1157075/000168316817001881/pharmacyte_10k-043017.htm
Quote:
"Did we lose our Chardan funding since the market cap dropped below the $75 million threshold this last quarter? My understanding was that they had to maintain this when each quarter report was due in order to keep the funding. Thanks in advance to anyone who can answer this truthfully."
If ViaCyte is subpar as you suggest how are they attracting so much support compared to pmcb which has 0?
Transforming the Lives of Patients with Diabetes
ViaCyte, Inc., a leader in the emerging field of regenerative medicine, is headquartered in San Diego, California. ViaCyte's innovative products are based on the differentiation of stem cells into pancreatic beta cell precursors (PEC-01™), with subcutaneous implantation in a retrievable medical device (Encaptra® cell delivery system). Once implanted, the precursor cells mature into endocrine cells that secrete insulin and other hormones in a regulated manner to control blood glucose levels. ViaCyte's goal is a product that can free patients with type 1 and type 2 diabetes from long-term insulin dependence. If successful, ViaCyte’s products will relieve patients of both the acute challenges and risks, as well as the long-term complications, associated with diabetes.
ViaCyte has received substantial financial, scientific, advocacy, and technical support from both the California Institute for Regenerative Medicine (CIRM) and JDRF.
http://viacyte.com
Have you heard ViaCyte just enrolled first human patients in FDA trial for t1 diabetes?? This is great news for T1 diabetics! A real company progressing with actual real trials. [/color=red]Not so great for pmcb though..... [/color] I took the liberty of posting this great news below for all to ENJOY! Finally a real company (ViaCyte) that's going to treat sickness people and not exploit them to make money off of like pmcb does! ViaCyte Announces First Patients Implanted with PEC-Direct Islet Cell Replacement Therapy in International Clinical Trial San Diego, August 1, 2017 — ViaCyte, Inc., a privately-held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC-Direct™ product candidate, a novel islet cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life-threatening complications. The first implant procedures of the clinical trial took place at the University of Alberta Hospital in Edmonton, Alberta, and the UC San Diego School of Medicine’s Altman Clinical Trials Research Institute. The goal of the open-label clinical trial is to evaluate the PEC-Direct product candidate for safety and definitive evidence of efficacy. In the coming months, the company expects to expand the trial to additional centers including the University of Minnesota and other sites in the US and Canada. The first cohort of type 1 diabetes patients is receiving multiple small-format cell-filled devices called sentinels in order to evaluate safety and implant viability. These sentinel units will be removed at specific time points and examined histologically to provide early insight into the progression of engraftment and maturation into pancreatic islet cells including insulin-producing beta cells. A second cohort of up to 40 patients is expected to begin enrolling later this year to evaluate both safety and efficacy. The primary efficacy measurement in the trial will be the clinically relevant production of insulin, as measured by the insulin biomarker C-peptide, in a patient population that has little to no ability to produce endogenous insulin at the time of enrollment. Other important endpoints will be evaluated including injectable insulin usage and the incidence of hypoglycemic events. ViaCyte’s goal is to demonstrate early evidence of efficacy in the first half of 2018 and definitive efficacy 6 to 12 months later. “Islet transplants have been used to successfully treat patients with unstable, high-risk type 1 diabetes, but the procedure has limitations, including a very limited supply of donor organs and challenges in obtaining reliable and consistent islet preparations,” said trial investigator James Shapiro, MD, PhD, FRCSC, Director of the Clinical Islet Transplant Program, University of Alberta. “An effective stem cell-derived islet replacement therapy would solve these issues and has the potential to help a greater number of people.” “Patients with high-risk type 1 diabetes complications, such as hypoglycemia unawareness, are at constant risk of life-threatening low blood glucose,” said Jeremy Pettus, MD, investigator in the clinical trial and Assistant Professor of Medicine at UC San Diego. “The PEC-Direct islet cell replacement therapy is designed to help patients with the most urgent medical need.” The PEC-Direct product candidate is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or severe hypoglycemic episodes. It is estimated that about 140,000 people in Canada and the US have such high-risk type 1 diabetes. In addition to providing an unlimited supply of cells for implantation, the PEC-Direct approach has other potential advantages relative to cadaver islet transplants such as delivering a more consistent product preparation under quality-controlled cGMP conditions, and a more straightforward and safe mode of delivery. The clinical trial is being supported in part by JDRF, the leading global organization funding type 1 diabetes research. “JDRF remains dedicated to accelerating the delivery of beta cell replacement therapies to the T1D community, and we commend ViaCyte in its announcement of the first patients to be implanted with the PEC-Direct islet cell replacement therapy,” said Derek Rapp, JDRF President and Chief Executive Officer. “JDRF is excited to support this clinical development given its potential to help those people with type 1 diabetes that need it the most – those at high risk of life-threatening acute complications. JDRF and ViaCyte share a continuing commitment to realizing the potential of beta cell replacement strategies to deliver insulin independence without immune suppression for people living with type 1 diabetes, and ultimately, at JDRF we hope this will move us forward in fulfilling our vision of a world without type 1 diabetes.” “There are limited treatment options for patients with high-risk type 1 diabetes to manage life-threatening hypoglycemic episodes,” said Paul Laikind, PhD, President and Chief Executive Officer of ViaCyte. “We believe that the PEC-Direct product candidate has the potential to transform the lives of these patients and we are excited to move closer to that goal with the initiation of clinical evaluation announced today. This also represents a step towards a broader application of the technology. We remain fully committed to developing a functional cure for all patients with insulin-requiring diabetes. To that end, we are hard at work on next-generation approaches as well, and expect the work with PEC-Direct to further advance our knowledge and drive progress.” In addition to JDRF, the California Institute for Regenerative Medicine (CIRM)’s Alpha Clinic, the Sanford Stem Cell Clinical Center, the JDRF Canadian Clinical Trials Network (CCTN), the Stem Cell Network, and Alberta Innovates Health Solutions (AIHS) are all providing support for the trial. About the PEC-Direct Product Candidate The PEC-Direct product candidate delivers stem cell-derived pancreatic progenitor cells, called PEC-01™ cells, in a device designed to allow direct vascularization of the cells in the device. After implantation, these cells are expected to become mature human islet tissue including well-regulated beta cells producing insulin on demand. The direct vascularization of the implanted cells is expected to allow for robust and consistent engraftment but will necessitate the use of maintenance immune suppression therapy. About ViaCyte ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte’s product candidates are based on the derivation of pancreatic progenitor cells from stem cells, which are then implanted in a durable and retrievable cell delivery device. Once implanted and matured, these cells are designed to secrete insulin and other pancreatic hormones in response to blood glucose levels. ViaCyte has two products in clinical development. The PEC-Direct™ product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap™ (also known as VC-01) product candidate delivers the same pancreatic progenitor cells in an immunoprotective device and is being developed for all patients with diabetes, type 1 and type 2, who use insulin. ViaCyte is headquartered in San Diego, California. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. http://viacyte.com/press-releases/viacyte-announces-first-patients-implanted-with-pec-direct-islet-cell-replacement-therapy-in-international-clinical-trial/
Pmcb lost to Viacyte for T1 diabetes. VC-01ViaCyte is developing islet cell replacement therapy for insulin-requiring diabetes. Our two key products in development deploy the same active component, PEC-01 Cells, but with different delivery technologies and addressing the unmet needs of different patient groups. The Human Trial is an independent, feature-length documentary that is in the works, currently following ViaCyte’s quest to develop what might become a functional cure for type 1 diabetes (T1D). http://viacyte.com
NOT GOOD FOR PMCB diabetes dream. ViaCyte (a private company) Announces First Patients Implanted with PEC-Direct Islet Cell Replacement Therapy in International Clinical Trial PR Newswire Aug. 1, 2017, 09:00 AM SAN DIEGO, Aug. 1, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC-Direct™ product candidate, a novel islet cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life-threatening complications. The first implant procedures of the clinical trial took place at the University of Alberta Hospital in Edmonton, Alberta, and the UC San Diego School of Medicine's Altman Clinical Trials Research Institute. The goal of the open-label clinical trial is to evaluate the PEC-Direct product candidate for safety and definitive evidence of efficacy. In the coming months, the company expects to expand the trial to additional centers including the University of Minnesota and other sites in the US and Canada. http://markets.businessinsider.com/news/stocks/ViaCyte-Announces-First-Patients-Implanted-with-PEC-Direct-Islet-Cell-Replacement-Therapy-in-International-Clinical-Trial-1002222558
Your welcome and should know Viacyte doesn't trade, it's a PRIVATE COMPANY.
It's great news for T1 diabetics though isn't it???
ViaCyte a real potential cure in actual human FDA clinical trials. Unlike the bullshit pipe dreams pmcb talks about.
So posts removed by mod squad show as "removed by admin" or get a "request review" option? Ive been having some deleted recently and admin said they didn't delete them and if mod squad did I would get the request review option. Admin did restore them after a pm but were stumped as am I on who did it.
Quote:
"You wouldn't see that. But if the deletion can be appealed at the "My Removed Posts" page, it was done by a board moderator. If it can't be appealed, it was done by an admin or a mod squadder. If yours fall into the latter category, you can always PM an admin asking what the problem was."